Praluent Outcomes data doomed?

[anonymous]

Praluent lowered the need for apheresis by 75% in HeFH. That is an invasive and expensive procedure so it is impressive that it was significantly reduced. What gets me concerned is the safety profile. Yet another study says that there are no safety concerns because the event rate is comparable to placebo(aka statin by itself). If this additional 50% reduction in LDL is so great why isn't it showing more heart attacks and events in the placebo arm? Why is it comparable? Managed care is not looking for surrogate markers like LDL reductions. They want hard evidence showing outcomes. We can say the study was not powered to prove event reductions but why aren't we even seeing a difference? Not good for the class so far.

 

[anonymous]

Praluent lowered the need for apheresis by 75% in HeFH. That is an invasive and expensive procedure so it is impressive that it was significantly reducedtoo bad it is not the 1990s u would all be rich by now you and Framingham look let's say fuzzy. No one pays for fuzzy these days buddy. at gets me concerned is the safety profile. Yet another study says that there are no safety concerns because the event rate is comparable to placebo(aka statin by itself). If this additional 50% reduction in LDL is so great why isn't it showing more heart attacks and events in the placebo arm? Why is it comparable? Managed care is not looking for surrogate markers like LDL reductions. They want hard evidence showing outcomes. We can say the study was not powered to prove event reductions but why aren't we even seeing a difference? Not good for the class so far.

 

[anonymous]

Praluent lowered the need for apheresis by 75% in HeFH. That is an invasive and expensive procedure so it is impressive that it was significantly reduced. What gets me concerned is the safety profile. Yet another study says that there are no safety concerns because the event rate is comparable to placebo(aka statin by itself). If this additional 50% reduction in LDL is so great why isn't it showing more heart attacks and events in the placebo arm? Why is it comparable? Managed care is not looking for surrogate markers like LDL reductions. They want hard evidence showing outcomes. We can say the study was not powered to prove event reductions but why aren't we even seeing a difference? Not good for the class so far.

Listen troll... 25% of pts taking statins can't achieve LDLs below 70mg/dl in the first place. Secondly, we aren't seeing a difference due to lack of events in the Praluent arm in the Outcomes data. Your other reference to the statin study and no difference -24 week study. Not outcomes. Take your inferences back to AstraZeneca and keep pushing that Crestor.